Skip to search formSkip to main contentSkip to account menu

Telcyta

National Institutes of Health

Related topics

Related topics

2 relations
TER 286

Broader (1)

TLK 286

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA).
Canfosfamide (TLK286, TELCYTA) is a prodrug that upon activation by glutathione transferase P1-1 (GST P1-1) yields an anticancer… 
Highly Cited
2009
Highly Cited
2009
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
Review
2008
Review
2008
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
Review
2006
Review
2006
Glutathione S-transferase polymorphisms: cancer incidence and therapy
The super family of glutathione S-transferases (GSTs) is composed of multiple isozymes with significant evidence of functional… 
Highly Cited
2006
Highly Cited
2006
A Glutathione S-Transferase π-Activated Prodrug Causes Kinase Activation Concurrent with S-Glutathionylation of Proteins
Nitric oxide (NO) is an endogenous, diffusible, transcellular messenger shown to affect regulatory and signaling pathways with… 
2006
2006
Multi-institutional Phase 2 Study of TLK286 (TELCYTA, a Glutathione S-transferase P1-1 Activated Glutathione Analog Prodrug) in Patients With Platinum and Paclitaxel Refractory or Resistant Ovarian…
Highly Cited
2005
Highly Cited
2005
Multi‐institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S‐transferase P1‐1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian…
The purpose of this study was to determine the safety and efficacy of TLK286 (TELCYTA™), a glutathione analog prodrug, in… 
2004
2004
Phase 1 Study of TLK286 (Telcyta) Administered Weekly in Advanced Malignancies
Purpose: To determine the dose-limiting toxicities, maximum tolerated dose, and pharmacokinetics of TLK286, a novel cancer… 
2004
2004
Synergistic effect of TELCYTA™ (TLK286) in combination with paclitaxel, doxorubicin, carboplatin, oxaliplatin, cisplatin, docetaxel, gemcitabine and iressa in human cancer cells.
2008 TLK286 is a novel glutathione analog cancer prodrug that has shown significant antitumor activity in multiple Phase 2… 
2004
2004
Phase 1–2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC)
7140 Background: TLK286 (Telcyta) is a novel glutathione analog prodrug activated by GST P1–1, which is overexpressed in NSCLC… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)